Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

Regulated gene transcription more complex than previously thought

Cells develop and thrive by turning genes on and off as needed in a precise pattern, a process known as regulated gene transcription. In a paper published in the Nov. 9 issue of the Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine say this process is even more complex than previously thought, with regulated genes actually relocated to other, more conducive places in the cell nucleus.

11 Nov 2011

Drug effectively combats obesity in “couch potato” monkeys” Study

According a new study an experimental anti-cancer drug could help fight obesity. The drug chokes off the blood supply to fat cells and helped obese monkeys slim down in the experiments.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

JMC launches comprehensive lung cancer program

Recruiting one of the nation's leading specialists in minimally-invasive lung and chest surgery, Jupiter Medical Center (JMC) has launched the first comprehensive program in Palm Beach and Martin counties dedicated to prevention, early detection, treatment and care of patients with lung cancer and other diseases of the chest and lung.

10 Nov 2011

Johns Hopkins researchers unravel how breast cancer metastasizes

The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. Now, the process by which it spreads—or metastasizes—has been unraveled by researchers at Johns Hopkins. Reporting in two papers, the researchers have discovered the switch that enables breast cancer cells to travel to and be received in the lungs.

9 Nov 2011

Viewpoints: Today's 'personhood' vote in Miss.; reactions to Romney's health care plan

What about in vitro fertilization, a process that both creates and discards embryos? What new rights would be afforded to a fetus, and how would those rights affect or compete with the rights of the woman who carries it? Would a woman who has an abortion be guilty of murder and subject to capital punishment? ... In their quest to ban abortion in Mississippi, the amendment's drafters appear to have rushed past such concerns.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

Teaching hospitals might provide better radical prostatectomy results

Prostate cancer patients who undergo radical prostatectomy get better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry Ford Hospital.

8 Nov 2011

Viewpoints: Weighing the ballot measures in Miss. and Ohio; the super committee's task

For all their sincerity and fervor, proponents of the personhood movement represent a small minority nationwide. In Gallup polls, support for a total abortion ban is almost exactly where it was in 1973 - at just over 20%, despite a rise in backing for limitations. Most people certainly don't want homicide charges brought against women who choose to have abortions or doctors who perform them.

8 Nov 2011

Prostate cancer drug market forecast to grow from $3.6 billion in 2010 to $10.1 billion in 2020

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Scientists discover how to starve prostate cancer cells

Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.

3 Nov 2011

Benefits of combined therapy for men with high-risk prostate cancer

Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease, shows clinical research led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network.

3 Nov 2011

TERE1 gene mutation also contributes to invasive bladder cancer

Research conducted by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology at LSU Health Sciences Center New Orleans, and colleagues has found that a defect in a gene involved in a rare disease of the cornea also contributes to the progression of invasive bladder cancer.

2 Nov 2011

Prostate cancer patients with bone metastases benefit from repeated 188Re-HEDP therapy

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

2 Nov 2011

Obama gets clean bill of health

President Barack Obama is in excellent health and tobacco free, his doctor said Monday in the results of the president’s second physical exam since taking office.

1 Nov 2011